SAP-001 is viewed as a novel clinical stage agent with disease modification potential for gout patientswith highly safe, efficacious, well-tolerated and easily administered.

Chronic pruritus occurs in 13% of the general population without age limitation and affects almost one fifth of the general population leading to great impairment of quality of life.